What is already known about this subject?
Atomoxetine is mainly metabolized by CYP2D6 with a secondary
involvement of CYP2C19.
Previous clinical studies have shown higher atomoxetine AUC,
Cmax and longer half-life in patients with the CYP2D6
poor metabolizer (PM) phenotype compared to normal metabolizers (NMs).
The CPIC dosing guidelines advise reducing the dose by 50% in CYP2D6
PMs, while potential dose adjustments according to CYP2C19genotype is not mentioned.